REAL-WORLD TRIPTAN UTILIZATION PATTERNS FOR ACUTE TREATMENT OF MIGRAINE AMONG 15 MILLION COMMERCIALLY INSURED LIVES

Migraine is a disabling disease impacting quality of life, productivity, and health care costs. Triptans are recommended as initial therapy for moderate/severe acute treatment of migraine. Limited real-world data assessing triptan utilization patterns among new initiators is available prior to approval of calcitonin-gene-related peptide inhibitors (CGRPs). The objectives are to describe new triptan initiators’ utilization, treatment switch and discontinuation, patterns in commercially insured members using claims data.